NEW KEYTRUDA (pembrolizumab) Clinical Trial
- This topic has 9 replies, 6 voices, and was last updated 7 years, 5 months ago by
.
-
Posts
-
Alikemal….I can’t answer the question about cost. You may have to reach out to Merck
https://www.merckaccessprogram-keytruda.com/For success you may want to peruse Matt’s postings:
CtWong: http://www.cholangiocarcinoma.org/punbb/viewtopic.php?id=12512
Matt: http://www.cholangiocarcinoma.org/punbb/search.php?action=show_user_posts&user_id=10126
Hugs
MarionThe UCSF trial closed quickly with 10 patients filling the 100 worldwide slots designated to cholangiocarcinoma patients.
OPDIVO® (nivolumab) and KEYTRUDA® (pembrolizumab) are identical and both can be prescribed off-label (believe cost to patient is approx. 17 thousand Dollars), or through the physician initiated expanded access program .Expanded Access (Compassionate Use)
Keytruda, Merck : http://www.merck.com/about/eap_faq.htmlOPDIVO – Bristol-Mayers-Scibb
http://www.bms.com/clinical_trials/investigator_sponsored_research/Pages/expanded-access-program.aspxHugs
MarionThank you so much for letting us know. I have kept one eye on Keytruda for many months. I was discouraged when I heard that the FDA cleared it only for a few types of cancer, but it opened the gate of promise for Trials. It sure would make all the headlines if it works well for many. I also wonder how long Keytruda has been in any trials in other countries?
Two people said they heard that it was only tested on people with a certain gene alteration. I hope and pray that isn’t true.
@middlesister1 – Mom’s still doing great.
Thanks for your kind words!
@lainy – Of course! We want to continue to spread awareness and hope! Take care!Hi Colleen, thank you for the great report on Keytruda! I have read so many good things and am hoping this gives us a turn in the road. Also hoping your Mom is doing well. I know a ton of members are going to really appreciate your post! Take care.
Hi All:
I just received details on a NEW clinical trial for KEYTRUDA. This is an international trial, targeting approx. 50 patients at UCSF.For more information, please visit: https://clinicaltrials.gov/ct2/show/NCT02628067?term=keynote+158&rank=
Or contact:
Wesley Goodman-Levy
Clinical Research Coordinator
Early Phase Investigational Therapeutics UCSF Helen Diller Family
Comprehensive Cancer Center
1600 Divisadero Street, Room B728K
Mailbox 1297
San Francisco, CA 94115
Tel: 415-514-6363
Fax: 415-514-6955The purpose of this study is to look at the effects, good or bad, of
pembrolizumab (MK-3475, also known as KEYTRUDA) on you and your
advanced solid tumors, to test the safety and tolerability of the
research study drug, pembrolizumab (MK-3475), and to see if
pembrolizumab(MK-3475) has anti-tumor activity in advanced solid tumors in patients
who have received prior treatment. Pembrolizumab is an investigational
drug, which has been approved for use in certain types of adult
melanoma. However the Food and Drug Administration (FDA) has not
approved pembrolizumab in any other cancers (including
advanced/unresectable or metastatic solid tumors). Your immune system
is designed to help your body fight off sickness. Some cancers are able to prevent the immune system from destroying the cancer cells. Pembrolizumab is a protein that is designed to block these effects and allow your body’s immune system to destroy the cancer cells.If you become part of this study you will take pembrolizumab every 3 weeks at a dose of 200 mg.
Pembrolizumab is administered as a 30 minute intravenous (IV) infusion
(though a needle in a vein your arm or other part of your body) on Day
1 of each treatment cycle. The time between doses of pembrolizumab
will be every 3 weeks. Your treatment may be withheld if you experience serious side effects.
- The forum ‘Clinical Trials’ is closed to new topics and replies.